- Home
- CRDL vs EVE Comparison
CRDL vs EVE Comparison
Compare CRDL & EVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- EVE
- Stock Information
- Founded
- CRDL 2017
- EVE 2021
- Country
- CRDL Canada
- EVE United States
- Employees
- CRDL N/A
- EVE N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- EVE Blank Checks
- Sector
- CRDL Health Care
- EVE Finance
- Exchange
- CRDL Nasdaq
- EVE Nasdaq
- Market Cap
- CRDL 140.1M
- EVE 159.3M
- IPO Year
- CRDL N/A
- EVE 2021
- Fundamental
- Price
- CRDL $2.27
- EVE $11.00
- Analyst Decision
- CRDL Strong Buy
- EVE
- Analyst Count
- CRDL 3
- EVE 0
- Target Price
- CRDL $9.00
- EVE N/A
- AVG Volume (30 Days)
- CRDL 257.3K
- EVE 12.0K
- Earning Date
- CRDL 08-12-2024
- EVE 01-01-0001
- Dividend Yield
- CRDL N/A
- EVE N/A
- EPS Growth
- CRDL N/A
- EVE 4067.26
- EPS
- CRDL N/A
- EVE 0.24
- Revenue
- CRDL N/A
- EVE N/A
- Revenue This Year
- CRDL N/A
- EVE N/A
- Revenue Next Year
- CRDL N/A
- EVE N/A
- P/E Ratio
- CRDL N/A
- EVE $45.05
- Revenue Growth
- CRDL N/A
- EVE N/A
- 52 Week Low
- CRDL $0.66
- EVE $10.63
- 52 Week High
- CRDL $3.12
- EVE $12.03
- Technical
- Relative Strength Index (RSI)
- CRDL 62.65
- EVE 44.51
- Support Level
- CRDL $1.78
- EVE $10.97
- Resistance Level
- CRDL $2.34
- EVE $11.07
- Average True Range (ATR)
- CRDL 0.12
- EVE 0.06
- MACD
- CRDL 0.05
- EVE -0.00
- Stochastic Oscillator
- CRDL 89.38
- EVE 75.51
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About EVE EVe Mobility Acquisition Corp
EVe Mobility Acquisition Corp is a blank check company.